Epoetin alfa improves quality of life in cancer patients
Author Information
Author(s): Fallowfield L, Gagnon D, Zagari M, Cella D, Bresnahan B, Littlewood T J, McNulty P, Gorzegno G, Freund M
Primary Institution: Cancer Research UK
Hypothesis
Does epoetin alfa improve the quality of life in anaemic cancer patients receiving non-platinum chemotherapy?
Conclusion
Epoetin alfa significantly improves the quality of life for anaemic cancer patients undergoing chemotherapy by increasing haemoglobin levels.
Supporting Evidence
- Epoetin alfa treatment led to a significant increase in haemoglobin levels compared to placebo.
- Patients receiving epoetin alfa reported better quality of life scores across multiple measures.
- Statistical analyses confirmed the benefits of epoetin alfa on quality of life were significant.
- Correlation analyses showed a positive relationship between haemoglobin levels and quality of life.
- Fewer patients in the epoetin alfa group required blood transfusions compared to the placebo group.
Takeaway
This study shows that a medicine called epoetin alfa can help cancer patients feel better by making their blood healthier.
Methodology
The study was a randomised, double-blind, placebo-controlled trial conducted in 15 countries with 375 patients, using multiple linear regression analyses to assess quality of life.
Potential Biases
Potential bias due to differences in reasons for patient dropout between treatment groups.
Limitations
The study focused on quality of life change from baseline to last assessment, which may introduce bias across treatment arms.
Participant Demographics
Patients had solid or non-myeloid haematologic malignancies and were receiving non-platinum chemotherapy.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website